Clinical outcomes and safety of the immune checkpoint inhibitor rechallenge in Hodgkin lymphoma: an off-trial analysis.
- DOI
- 10.3324/haematol.2026.301311
- Published
- 2026 Sep 24
- Container
- Haematologica
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3324/haematol.2026.301311,
title = {Clinical outcomes and safety of the immune checkpoint inhibitor rechallenge in Hodgkin lymphoma: an off-trial analysis.},
author = {Nishimura Y and Maiocco J and Janda G and Nedved A and Han Y and Durani U and Nowakowski GS and Paludo J and Thanarajasingam G and Micallef I and Johnston P and Witzig T and Habermann T and Maurer M and Armand P and Ansell SM and Abeykoon J},
year = {2026},
journal = {Haematologica},
doi = {10.3324/haematol.2026.301311},
url = {https://doi.org/10.3324/haematol.2026.301311}
}RIS
TY - JOUR TI - Clinical outcomes and safety of the immune checkpoint inhibitor rechallenge in Hodgkin lymphoma: an off-trial analysis. AU - Nishimura Y AU - Maiocco J AU - Janda G AU - Nedved A AU - Han Y AU - Durani U AU - Nowakowski GS AU - Paludo J AU - Thanarajasingam G AU - Micallef I AU - Johnston P AU - Witzig T AU - Habermann T AU - Maurer M AU - Armand P AU - Ansell SM AU - Abeykoon J PY - 2026 JO - Haematologica DO - 10.3324/haematol.2026.301311 UR - https://doi.org/10.3324/haematol.2026.301311 ER -
APA
Y, N., J, M., G, J., A, N., Y, H., U, D., GS, N., J, P., G, T., I, M., P, J., T, W., T, H., M, M., P, A., SM, A., & J, A. (2026). Clinical outcomes and safety of the immune checkpoint inhibitor rechallenge in Hodgkin lymphoma: an off-trial analysis.. Haematologica. https://doi.org/10.3324/haematol.2026.301311